Valuation: Arcellx, Inc.

Market Cap 6.75B 6B 5.61B 5.11B 9.62B 650B 9.75B 67.84B 26.26B 331B 25.35B 24.8B 1,063B P/E 2024
-38.3x
P/E 2025 -16x
Enterprise Value 6.28B 5.58B 5.22B 4.76B 8.95B 605B 9.08B 63.14B 24.44B 308B 23.59B 23.08B 990B EV / Sales 2024
33,125,319x
EV / Sales 2025 148,161,186x
Free-Float
88.44%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Arcellx, Inc.

1 day+0.03%
6 months+0.22%
Current year+76.49%
Current year 60.36
Extreme 60.355
115.13
1 year 60.36
Extreme 60.355
115.13
3 years 30.88
Extreme 30.88
115.13
5 years 6.04
Extreme 6.035
115.13
10 years 6.04
Extreme 6.035
115.13
Date Insider Type Main position Quantity % Market Cap. Importance
28/4/26 Tender

Director

216,666 0.3705%
28/4/26 Tender

Chief Executive Officer

5,603,097 9.5813%
28/4/26 Issuer sale

Director

76,234 0.1304%
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%-.--%+40.16%+220.71% 6.75B
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.61%+0.81%+27.25%+80.21% 60.14B
-2.54%-1.65%+4.86%+33.32% 48.15B
-1.72%-4.15%+29.36%+35.97% 44.25B
+2.09%+4.66%+356.11%+699.27% 43.99B
-1.21%+0.40%+7.83%+102.46% 41.61B
+3.32%+3.49%+11.18%+51.23% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-2.83%-8.78%-24.72%+337.03% 24.93B
Average +0.56%+1.78%+53.82%+167.72% 40.36B
Weighted average by Cap. +0.73%+1.80%+59.24%+154.01%

Financials

2024 2025
Net sales 107.94 95.87 89.65 81.7 153.81 10.39K 155.92 1.08K 419.86 5.29K 405.25 396.46 17K 22.29 19.79 18.51 16.87 31.76 2.15K 32.19 223.94 86.69 1.09K 83.67 81.86 3.51K
Net income -107M -95.35M -89.17M -81.25M -153M -10.34B -155M -1.08B -418M -5.26B -403M -394M -16.91B -229M -203M -190M -173M -326M -22.04B -331M -2.3B -891M -11.23B -860M -841M -36.06B
Net Debt -572M -508M -475M -433M -814M -55.03B -826M -5.74B -2.22B -28.03B -2.15B -2.1B -90.02B -468M -416M -389M -354M -667M -45.07B -676M -4.7B -1.82B -22.95B -1.76B -1.72B -73.73B
Logo Arcellx, Inc.
Arcellx Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering immunotherapies for patients with cancer and other incurable diseases. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. It is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Employees
209
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. ACLX Stock